11 June 2019 - Last month, the Biosimilars Forum released a proposal that it said could save the United States and taxpayers billions of dollars in Medicare Part B, depending on which changes Congress decided to make, such as creating new innovation models, using a shared savings program, or upping add-on payments.

The industry group said it commissioned a scoring analysis from Avalere Health examining options that could potentially reduce out-of-pocket costs and federal spending in the range of $1.9 billion to $5.2 billion between 2020 and 2029, and cut beneficiary costs by $2.2 billion to $3.3 billion.

The estimates vary based on the underlying assumptions used, and they vary widely. In that sense, it is similar to other reports that have strategised ways to increase the uptake of biosimilars in the United States, where they have about 2% of the total biologics market, and outcomes depends on a lot of other factors, said one observer.

Read Center for Biosimilars article